Daniele Assad Suzuki (BRA)
Graduated in Medicine from the University of Brasilia; Residency in Internal Medicine at Hospital de Base do Distrito Federal; Residency in Clinical Oncology at the National Cancer Institute (INCA)-RJ; Master’s and Doctorate in Health Sciences from the University of Brasília; Member of the Board of Directors of the Brazilian Group of Gynecological Tumors (EVA) and Member of the Breast Committee of the Brazilian Society of Clinical Oncology (SBOC); Oncologist at the Oncology Center at Hospital Sírio-Libanês- Brasília; Gynecological Cancer and Breast Cancer as main areas of expertise.
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
Management of key adverse events in hormone therapy: what is the real evidence?
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
What will be the status of the treatment algorithm within metastatic HER2-positive disease with the introduction of trastuzumab-deruxtecan?
MAIN AUDITORIUM
Silver Satellite Symposium - Lilly: From early stages to metastatic cancer: updates on abemaciclib in the treatment of HR+ HER2- breast cancer
MAIN AUDITORIUM
